Latest filings (excl ownership)
10-K
2023 FY
Annual report
8 Mar 24
8-K
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
7 Mar 24
8-K
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
4 Mar 24
8-K
Results of Operations and Financial Condition
10 Jan 24
8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
8 Dec 23
8-K
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
7 Dec 23
424B5
Prospectus supplement for primary offering
7 Dec 23
424B5
Prospectus supplement for primary offering
4 Dec 23
8-K
Other Events
4 Dec 23
8-K
Other Events
9 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments
1 Nov 23
EFFECT
Notice of effectiveness
31 Oct 23
CORRESP
Correspondence with SEC
26 Oct 23
UPLOAD
Letter from SEC
25 Oct 23
S-3
Shelf registration
20 Oct 23
S-8
Registration of securities for employees
20 Oct 23
8-K
EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team
16 Oct 23
8-K
Other Events
13 Sep 23
8-K
Other Events
11 Sep 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
8-K
EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments
2 Aug 23
8-K
Other Events
27 Jul 23
8-K
Other Events
11 Jul 23
8-K
EyePoint Pharmaceuticals Announces Chief Executive Officer Transition
10 Jul 23
8-K
Departure of Directors or Certain Officers
21 Jun 23
8-K
EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathy
5 Jun 23
8-K/A
Financial Statements and Exhibits
23 May 23
8-K
EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties
18 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Developments
3 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD
27 Mar 23
8-K
Other Events
10 Mar 23
10-K
2022 FY
Annual report
10 Mar 23
8-K
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments
2 Mar 23
8-K
Entry into a Material Definitive Agreement
23 Jan 23
8-K
Other Events
12 Jan 23
S-8
Registration of securities for employees
9 Jan 23
Latest ownership filings
4
Dario A. Paggiarino
2 Apr 24
4
Ramiro Ribeiro
4 Mar 24
3
Ramiro Ribeiro
4 Mar 24
4
Jay S. Duker
28 Feb 24
4
Jay S. Duker
22 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
4
Nancy Lurker
13 Feb 24
4
Dario A. Paggiarino
13 Feb 24
4
David Scott Jones
13 Feb 24
4
George Elston
13 Feb 24
4
Jay S. Duker
13 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
SC 13G/A
FRANKLIN RESOURCES INC
6 Feb 24
4
David Scott Jones
5 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
4
Dario A. Paggiarino
30 Jan 24
4
David Scott Jones
29 Jan 24
4
Dario A. Paggiarino
29 Jan 24
4
David Scott Jones
26 Jan 24
4
Dario A. Paggiarino
25 Jan 24
4
Nancy Lurker
25 Jan 24
4
David Scott Jones
24 Jan 24
144
Notice of proposed sale of securities
24 Jan 24
144
Notice of proposed sale of securities
24 Jan 24
144
Notice of proposed sale of securities
23 Jan 24
144
Notice of proposed sale of securities
23 Jan 24
144
Notice of proposed sale of securities
22 Jan 24
4
Therapeutics Ocumension
16 Jan 24
4
Ye Liu
16 Jan 24
144
Notice of proposed sale of securities
11 Jan 24
4
Bihua Chen
11 Jan 24
4
Dario A. Paggiarino
10 Jan 24
4
Dario A. Paggiarino
9 Jan 24
4
Nancy Lurker
9 Jan 24
4
Karen L. Zaderej
9 Jan 24
4
Michael Craig Pine
9 Jan 24
4
David Scott Jones
9 Jan 24
4
Jay S. Duker
9 Jan 24